The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ICML 2019 | The revised role of targeted approaches in indolent lymphoma

Jun 27, 2019
Share:

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Martin Dreyling from University of Munich (LMU), Munich, DE, about the revised role of targeted approaches in indolent lymphoma.

Martin Dreyling also spoke of the disappointing results of the large phase III study, discussed in the plenary session, looking at treating aggressive lymphoma with lenalidomide and standard-of-care, R-CHOP.

The revised role of targeted approaches in indolent lymphoma

Share: